19
Participants
Start Date
February 28, 2014
Primary Completion Date
March 31, 2015
Study Completion Date
June 30, 2015
IGN523
Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
Winship Cancer Institute, Emory University, Atlanta
Indiana Blood and Marrow Transplantation Clinic, Indianapolis
University of Michigan Health System, Ann Arbor
MD Anderson Cancer Center, Houston
UCSD Medical Center / Thornton Hospital, La Jolla
University of Washington, Seattle
Lead Sponsor
Igenica Biotherapeutics, Inc.
INDUSTRY